QURE Share Price Performance
US$0
-13.15 (-100.00%)
Price US$0
Fair ValueUS$38.48
Share Pricen/a
Seeking Alpha • 8h
uniQure N.V. Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 29 Fair Values set on narratives written by author
QURE Community Narratives
AN
Fair Value
·Fair Value US$38.48 24.4% undervalued intrinsic discount
QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake
1users have liked this narrative
1users have commented on this narrative
11users have followed this narrative
AN
Fair Value
·Fair Value US$90.71 67.9% undervalued intrinsic discount
Huntington’s Gene Therapy And Rare Disease Pipeline Will Reshape Long Term Outcomes
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value
·Fair Value US$33.36 12.8% undervalued intrinsic discount
Tighter Gene Therapy Regulations And Safety Risks Will Challenge Neurology Pipeline Yet Offer Long-Term Promise
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
QURE: Pivotal Three-Year Huntington’s Data Will Drive Approval and Market Uptake
Key Takeaways Accelerated approval of AMT-130 for Huntington's could significantly boost future revenues as it would be a pioneering treatment. Strategic financial actions and strong cash reserves provide resilience and flexibility, supporting pipeline advancement and likely improving margins.Read more
AN
US$38.48
24.4% undervalued intrinsic discount
Fair Value
Profit Margin
12.92%
Future PE
186.36x
Price in 2029
US$47.6
Huntington’s Gene Therapy And Rare Disease Pipeline Will Reshape Long Term Outcomes
Catalysts About uniQure uniQure develops gene therapies targeting serious neurological and rare metabolic diseases. What are the underlying business or industry changes driving this perspective?Read more
AN
US$90.71
67.9% undervalued intrinsic discount
Fair Value
Profit Margin
27.81%
Future PE
51.51x
Price in 2029
US$111.79
Tighter Gene Therapy Regulations And Safety Risks Will Challenge Neurology Pipeline Yet Offer Long-Term Promise
Catalysts About uniQure uniQure develops gene therapies targeting severe neurological and metabolic rare diseases. What are the underlying business or industry changes driving this perspective?Read more
AN
US$33.36
12.8% undervalued intrinsic discount
Fair Value
Profit Margin
16.03%
Future PE
479.71x
Price in 2028
US$41.29
Trending Discussion
Recently Updated Narratives
AN
QURE: FDA Leadership Shift Will Reshape Gene Therapy Approval Path
Fair Value: US$38.48 24.4% undervalued intrinsic discount
11 fair values setusers have set this as their fair value
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Huntington’s Gene Therapy And Rare Disease Pipeline Will Reshape Long Term Outcomes
Fair Value: US$90.71 67.9% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Tighter Gene Therapy Regulations And Safety Risks Will Challenge Neurology Pipeline Yet Offer Long-Term Promise
Fair Value: US$33.36 12.8% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
uniQure N.V. Key Details
Last Reported Earnings
Mar 31, 2026
Next Reporting Earnings
n/a
- -3.31
- -613.92%
- -1,154.42%
- 356.4%
About QURE
- Founded
- 1998
- Employees
- 221
- CEO
- WebsiteView website
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in phase I/II clinical study for the treatment of Huntington’s disease. The company also develops AMT-260, which is in phase I/IIa clinical trial for the treatment of mesial temporal lobe epilepsy; AMT-162, which is in phase I/IIa clinical trial to treat superoxide dismutase enzyme-amyotrophic lateral sclerosis; and AMT-191, an investigational gene therapy candidate which is in phase I/IIa clinical trial for the treatment of fabry disease. It has a licensing agreement with Apic Bio to develop, manufacture, and commercialize intrathecally administered investigational gene therapy for ALS caused by mutations in SOD-1; and development and commercial supply agreement with CLS Bhering. uniQure N.V. was founded in 1998 and is headquartered in Amsterdam, the Netherlands.
